Stockreport

Upcoming Obicetrapib Phase 3 Data at ACC.26 Might Change The Case For Investing In NewAmsterdam Pharma (NAMS) [Yahoo! Finance]

NewAmsterdam Pharma Company N.V. - Ordinary Shares  (NAMS) 
PDF at the American College of Cardiology Annual Scientific Session (ACC.26) in New Orleans on March 28–30, 2026, including results from the Phase 3 BROADWAY trial and poole [Read more]